Table 2 The prevalence of constipation and diarrhoea among users and non-users of drugs significantly associated with the complaints (bivariate analyses, all participants)
ATC level | ATC code | Name of drug group/chemical substance | Prevalence (%) Users/non users | Statistics (p-value) | |
|---|---|---|---|---|---|
Constipation | Level 4 | C10AA | HMG CoA reductase inhibitors | 18.5/13.6 | 0.033 |
M01AE | Propionic acid derivatives | 18.7/13.3 | 0.001 | ||
N06AA | Non-selective monoamine reuptake inhibitors | 23.2/13.7 | 0.050 | ||
Level 5 | C01AA04 | Digitoxin | 38.5/13.8 | 0.025 | |
C01DA02 | Glyceryl trinitrate | 27.3/13.7 | 0.015 | ||
C03CA01 | Furosemide | 29.2/13.6 | 0.001 | ||
C10AA05 | Atorvastatin | 21.4/13.7 | 0.037 | ||
G03CX01 | Tibolone | 40.0/13.8 | 0.038 | ||
H03AA01 | Levothyroxine sodium | 28.1/13.4 | <0.001 | ||
M01AE01 | Ibuprofen | 19.4/13.3 | 0.001 | ||
Diarrhoea | Level 4 | C10AA | HMG CoA reductase inhibitors | 12.7/8.6 | 0.031 |
R06AD | Phenothiazine derivatives | 28.6/8.7 | 0.029 | ||
Level 5 | A10BA02 | Metformin | 30.8/8.7 | 0.022 | |
C03EA01 | Hydrochlorothiazide and potassium-sparing agents | 25.0/8.7 | 0.009 | ||
C07AB02 | Metoprolol | 13.3/8.6 | 0.026 | ||
N03AF01 | Carbamazepine | 25.0/8.7 | 0.009 | ||
N05AN01 | Lithium | 33.3/8.7 | 0.017 | ||
N06AB05 | Paroxetine | 19.6/8.7 | 0.012 | ||
R03BA01 | Beclometasone | 28.6/8.7 | 0.029 |